HIGHLIGHTS
- who: April and colleagues from the University, United States have published the research work: Ef cacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China, in the Journal: (JOURNAL) of August/24,/2022
- what: All procedures performed in this study were in accordance with the Declaration of Helsinki (revised 2013). characteristics and efficacy data of the two treatment groups were compared using the c2 test or Wilcoxon rank sum test. The study showed no significant difference between the two groups in terms of median . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.